drugset
Drugs / Calmangafodipir
last change Nov 2022 re-read 2 minutes ago

Calmangafodipir

also known as Calmangafodipir (ca4mn(dpdp)5) · CaM · PledOx · PP100-01

Small molecule

Developed for
chemotherapy-induced neuropathy · colorectal cancer · paracetamol poisoning
Investigated by
Egetis Therapeutics · Solasia Pharma K.K. · NHS Lothian · University of Edinburgh

Trials 4 · a red edge is where a trial was stopped

today NCT04034355 · Ph 3 NCT03654729 · Ph 3 NCT03430999 · Ph 1 NCT03177395 · Ph 1
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT03430999 Nov → Dec 2017 chemotherapy-induced neuropathy Egetis Therapeutics Completed No outcome recorded
Phase 1 NCT03177395 Jun 2017 → Aug 2018 paracetamol poisoning Egetis Therapeutics Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04034355 Jan 2019 → Aug 2020 chemotherapy-induced neuropathy, colorectal cancer Egetis Therapeutics Terminated No outcome recorded
Phase 3 NCT03654729 Nov 2018 → Aug 2020 chemotherapy-induced neuropathy, colorectal cancer Egetis Therapeutics Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01619423 Comparator Sep 2012 → Mar 2016 colorectal cancer Egetis Therapeutics Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Calmangafodipir “PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.” NCT01619423 ↗
4

NCT03654729 ↗

NCT04034355 ↗

NCT03430999 ↗

NCT03177395 ↗
Known as Calmangafodipir (ca4mn(dpdp)5) ChEMBL registry synonym — accepted as the source's own label CHEMBL4297714 ↗
Known as CaM “Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients...” PMID 36308441 ↗ Nov 2022
Known as PledOx “Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)): a placebo-controlled randomised phase II study (PLIANT).” PMID 29140155 ↗ Nov 2017
Known as PP100-01 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297714 ↗
Modality Small molecule “the manganese chelate and superoxide dismutase mimetic mangafodipir (MnDPDP) and calmangafodipir ([Ca0.8,Mn0.2]Na3DPDP)” NCT03654729 ↗
Route Intravenous “PP100-01 treatment is administered intravenously over 5 minutes.” NCT03177395 ↗